Sorafenib
8
2
2
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
25.0%
2 terminated out of 8 trials
60.0%
-26.5% vs benchmark
50%
4 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT
A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
Fingerprint Characterization Tyrosine Kinase Inhibitors in Advanced HCC
TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma
Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)
Combined Treatment of RFA and Sorafenib on Recurrent HCC